10-Q: Johnson & Johnson Reports Strong Q2 Earnings Driven by Talc Reserve Reversal and Strategic Acquisitions

Johnson & Johnson's second quarter and first half 2025 financial results show significant net earnings growth, primarily due to the reversal of a substantial talc litigation reserve, alongside robust performance in Innovative Medicine and MedTech segments boosted by recent acquisitions.

Summary

• Worldwide sales for the fiscal second quarter of 2025 increased by 5.8% to $23.7 billion, with operational growth of 4.6% and a positive currency impact of 1.2%.
• For the fiscal six months ended June 29, 2025, worldwide sales were $45.6 billion, a 4.1% increase, including an operational increase of 4.4%.
• Net earnings for the fiscal second quarter of 2025 were $5.537 billion, up from $4.686 billion in the prior year, representing 23.3% of sales.
• Net earnings for the fiscal six months of 2025 surged to $16.536 billion, compared to $7.941 billion in the prior year, representing 36.2% of sales.
• The significant increase in six-month net earnings is primarily due to the reversal of approximately $7.0 billion of the previously accrued talc reserve.
• Diluted net earnings per share for Q2 2025 were $2.29, up from $1.93 in Q2 2024, and for the six months were $6.82, up from $3.27 in the prior year.
• Innovative Medicine segment sales grew 4.9% operationally in Q2 2025 and 4.0% operationally for the six months, driven by Oncology and Neuroscience products.
• MedTech segment sales increased 6.1% operationally in Q2 2025 and 5.1% operationally for the six months, significantly boosted by the Shockwave acquisition and strong Cardiovascular performance.
• The company completed the acquisition of Intra-Cellular Therapies, Inc. for $14.5 billion on April 2, 2025, adding CAPLYTA to its mental health portfolio.
• The acquisition of Shockwave Medical Inc. for $12.6 billion on May 31, 2024, contributed significantly to MedTech sales.
• Total assets increased to $193.389 billion as of June 29, 2025, from $180.104 billion at December 29, 2024, largely due to increased intangible assets and goodwill from acquisitions.
• Long-term debt increased to $39.235 billion as of June 29, 2025, from $30.651 billion at December 29, 2024, reflecting financing for acquisitions.
• Cash and cash equivalents decreased to $18.577 billion as of June 29, 2025, from $24.105 billion at December 29, 2024, primarily due to investing activities related to acquisitions.
• The company recorded a one-time re-measurement cost of approximately $1.0 billion related to the new U.S. tax legislation (OBBBA) in the fiscal third quarter.
• Ongoing restructuring programs in MedTech's Surgery and Orthopaedics franchises incurred expenses of $29 million and $50 million, respectively, in Q2 2025.

Sentiment

Score: 8

Explanation: The significant reversal of the talc litigation reserve, leading to a substantial increase in net earnings, is a major positive. Strong operational growth in key segments, driven by strategic acquisitions, further enhances the positive outlook. While challenges like biosimilar competition for STELARA and increased debt exist, the overall financial performance and strategic moves indicate a strong position.

Positives

• Net earnings for the fiscal six months of 2025 significantly increased to $16.536 billion, primarily due to the reversal of approximately $7.0 billion of the previously accrued talc reserve.
• Innovative Medicine segment achieved strong operational sales growth of 4.0% for the fiscal six months, driven by key products.
• Oncology product sales grew operationally by 22.3% in Q2 2025 and 21.3% for the six months, with strong performance from DARZALEX, ERLEADA, CARVYKTI, TECVAYLI, TALVEY, and RYBREVANT/LAZCLUZE.
• MedTech segment demonstrated robust operational sales growth of 6.1% in Q2 2025 and 5.1% for the six months, boosted by recent acquisitions.
• Cardiovascular franchise sales in MedTech surged by 22.3% operationally in Q2 2025, largely due to the Shockwave acquisition and strong Abiomed performance.
• SPRAVATO sales in Neuroscience grew significantly by 53.0% operationally in Q2 2025 due to increased physician and patient demand.
• The company successfully completed the acquisition of Intra-Cellular Therapies, Inc. for $14.5 billion, adding CAPLYTA, an FDA-approved treatment for bipolar I and II depression and schizophrenia, and a promising clinical-stage pipeline.
• The acquisition of Shockwave Medical Inc. for $12.6 billion strengthened the MedTech portfolio with innovative intravascular lithotripsy technology.
• The company secured a new $10 billion 364-day Credit Facility, enhancing liquidity and financial flexibility.
• The worldwide effective income tax rate for the fiscal six months of 2025 benefited from changes in uncertain international tax positions due to expiration of statute of limitations.

Negatives

• STELARA sales experienced a significant operational decline of 43.2% in Q2 2025 and 38.2% for the six months, primarily due to biosimilar competition and Medicare Part D redesign, negatively impacting worldwide operational sales growth by approximately 7.1% in Q2 and 5.9% for the six months.
• IMBRUVICA sales declined operationally by 6.6% in Q2 2025 and 6.6% for the six months due to competitive pressures and Medicare Part D redesign.
• ZYTIGA/abiraterone acetate sales declined operationally by 14.9% in Q2 2025 and 21.9% for the six months due to loss of exclusivity.
• Infectious Disease products saw a substantial operational sales decline of 19.0% in Q2 2025 and 10.2% for the six months, partly due to the absence of COVID-19 vaccine revenue.
• Orthopaedics franchise experienced an operational sales decline of 1.6% in Q2 2025 and 2.3% for the six months, impacted by revenue disruption from restructuring, China volume-based procurement, and competitive pressures.
• Cash and cash equivalents decreased by $5.528 billion for the fiscal six months ended June 29, 2025, primarily due to significant cash used in investing activities for acquisitions.
• Net debt position increased to $31.9 billion as of June 29, 2025, compared to $16.0 billion a year prior, due to higher average debt balance at higher interest rates.
• The company expects a one-time re-measurement cost of approximately $1.0 billion in the fiscal third quarter due to new U.S. tax legislation (OBBBA).
• Cost of products sold increased as a percentage of sales due to unfavorable product mix (STELARA decline), increased intangible asset amortization from acquisitions, and macroeconomic factors.
• Interest expense was higher due to a higher average debt balance at higher interest rates, while interest income decreased due to lower interest rates earned on cash balances.

Risks

• Challenges and uncertainties inherent in innovation and development of new products, including clinical outcomes, regulatory approvals, and commercial success.
• Ability to secure and maintain adequate patent and other intellectual property rights, facing aggressive challenges from competitors and potential loss of market exclusivity.
• Impact of patent expirations and introduction of competing generic or biosimilar products, leading to revenue and market share losses (e.g., STELARA).
• Product efficacy or safety concerns, potentially resulting in product withdrawals, recalls, regulatory action, declining sales, and reputational damage.
• Impact of significant litigation or government action, including product liability claims (talc, opioid, ASR, PINNACLE, pelvic meshes, Physiomesh, ELMIRON) and allegations related to pharmaceutical marketing practices.
• Uncertainty of ultimate outcome of legal proceedings and adequacy of reserves, with potential for material adverse effects on results of operations and cash flows.
• Increased scrutiny of the healthcare industry by government agencies, carrying risks of significant civil and criminal penalties.
• Failure to meet compliance obligations in agreements with governments or government agencies, which could result in significant sanctions.
• Potential changes to applicable laws and regulations affecting operations, including product approval, licensing, patent rights, sales, reimbursement, environmental protection, and raw material sourcing.
• Compliance with local regulations and laws that may restrict manufacturing or sales, such as medical device reporting regulations and EU Medical Devices Regulation.
• Changes in domestic and international tax laws and regulations, increasing audit scrutiny, and potential for additional tax liabilities (e.g., OBBBA, Pillar Two Directive).
• Pricing pressures from healthcare cost containment trends, managed care, government payors, and new market entrants.
• Challenges in realizing growth strategies through externally sourced innovations due to competitive pressures and heightened costs.
• Potential that expected strategic benefits from acquisitions or divestitures may not be realized or may take longer than expected.
• Potential that expected benefits from restructuring actions may not be realized or may take longer than expected.
• Risks associated with global operations, including foreign governments, inflation, interest rate and currency exchange rate fluctuations.
• Potential changes in export/import and trade laws, regulations, and policies, including increased trade restrictions or tariffs.
• Impact on international operations from financial instability, sovereign risk, governmental controls, and unstable international governments.
• Impact of global public health crises and pandemics.
• Changes to global climate, extreme weather, and natural disasters affecting demand, supply chains, and operations.
• Impact of global or economic changes or events, including global tensions and war (e.g., Russia-Ukraine, Middle East conflict).
• Difficulties and delays in manufacturing, leading to business interruptions, product shortages, or regulatory action.
• Interruptions and breaches of information technology systems, resulting in business harm, financial costs, and regulatory action.
• Reliance on complex global supply chains subject to increasing regulatory requirements affecting supply, sourcing, and pricing.

Future Outlook

The company anticipates continued launches of biosimilar versions of STELARA in Europe and the United States in 2025, which will impact STELARA sales. It expects to continue its practice of paying regular quarterly cash dividends. The company is still assessing the full impact of the newly enacted One Big Beautiful Bill Act (OBBBA) tax legislation, estimating a one-time re-measurement cost of approximately $1.0 billion in the fiscal third quarter. Ongoing restructuring programs in MedTech's Surgery and Orthopaedics franchises are expected to be completed over the next two years and by the end of fiscal year 2025, respectively. The company will continue to monitor further developments regarding the EU's Pillar Two Directive and other global tax law changes. Litigation related to the IRA's Medicare Drug Price Negotiation Program remains ongoing, with an appeal filed by Janssen to the Third Circuit.

Management Comments

• Management believes the ultimate outcome of legal proceedings, net of liabilities accrued, is not expected to have a material adverse effect on the company's financial position.
• Management continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed.
• Management is pursuing four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims.
• Management believes its policy regarding 340B contract pharmacy transactions will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute.
• Management anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities, and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs.

Industry Context

The pharmaceutical and medical technologies industries are facing increasing pricing pressures due to healthcare cost containment trends, including managed care and government becoming primary payors. Biosimilar competition, exemplified by the significant decline in STELARA sales, continues to be a major factor impacting revenue for established blockbuster drugs. Regulatory scrutiny from government agencies remains high, leading to investigations and litigation. Global economic conditions, including inflation and currency fluctuations, and geopolitical tensions (Russia-Ukraine, Middle East) also pose ongoing challenges to international operations and supply chains. The industry is also adapting to new tax legislation like the U.S. OBBBA and the EU's Pillar Two Directive, which could impact effective tax rates and deferred tax balances.

Comparison to Industry Standards

• The significant decline in STELARA sales due to biosimilar competition is a common challenge faced by pharmaceutical companies as patents expire, similar to how Humira (AbbVie) has faced biosimilar erosion.
• The company's strategy of acquiring innovative companies like Intra-Cellular Therapies (focused on CNS disorders) and Shockwave Medical (intravascular lithotripsy) aligns with broader industry trends of M&A to bolster pipelines and expand into high-growth medical technology areas, comparable to recent acquisitions by Medtronic or Boston Scientific in the MedTech space, or Pfizer and Merck in pharmaceuticals.
• The ongoing talc and opioid litigation, while specific to the company, reflects a broader trend of increased product liability and mass tort litigation impacting large pharmaceutical and consumer goods companies, such as Bayer's Roundup litigation or Purdue Pharma's opioid settlements.
• The restructuring initiatives in MedTech's Surgery and Orthopaedics franchises are consistent with industry-wide efforts by large diversified healthcare companies to streamline operations, optimize portfolios, and improve efficiency in competitive markets, similar to portfolio adjustments seen at Zimmer Biomet or Stryker.

Corporate Governance

Legal Proceedings

• Talc: Reversal of approximately $7.0 billion from previously accrued talc reserve due to dismissal of Red River Bankruptcy Case on March 31, 2025. Total present value of reserve is now approximately $4.0 billion. Company returned to tort system to litigate claims, with bellwether trials scheduled for November 2025 (California JCCP) and January 2026 (New Jersey MCL). Ongoing appeals by insurers regarding the Imerys Settlement Agreement.
• Opioid: Approximately 80% of the $5.0 billion settlement paid by end of Q2 2025. Agreement reached to resolve hospital cases in September 2024. Under 27 remaining cases in state courts, 290 in Ohio MDL, and 2 in other federal courts. Class action certified in British Columbia, Canada, with appeals filed by defendants. Shareholder derivative complaints dismissed and appeals exhausted.
• Product Liability (General): Accruals for loss contingencies when probable and estimable. Significant cases include: Body powders containing talc (70,030 plaintiffs), DePuy ASR Hip Systems (40 plaintiffs), PINNACLE Acetabular Cup System (860 plaintiffs), Pelvic meshes (5,350 plaintiffs), ETHICON PHYSIOMESH Flexible Composite Mesh (120 plaintiffs), ELMIRON (920 plaintiffs).
• Intellectual Property: Lawsuits against generic manufacturers for XARELTO, INVEGA SUSTENNA, INVEGA TRINZA, ERLEADA, SPRAVATO, INVOKANA, and CAPLYTA. Recent developments include Federal Circuit affirming INVEGA SUSTENNA patent validity (July 2025), denial of Mylan's rehearing petition for INVEGA TRINZA (July 2025), and confidential settlement for CAPLYTA with Hetero (July 2025). Abiomed's patent litigation against Maquet continues with partial remand.
• Government Proceedings: DOJ Civil Investigative Demands to J&J Vision regarding False Claims Act investigation related to free/discounted intraocular lenses and equipment. Qui tam complaint against Janssen Products, LP for off-label promotion of PREZISTA and INTELENCE and anti-kickback violations, with jury finding liability for off-label claims (June 2024) and company appealing (April 2025). DOJ closed investigation into Janssen Biotech, Inc. regarding REMICADE/SIMPONI ARIA services.
• General Litigation: Lawsuit by U.S. service members against the Company alleging Anti-Terrorism Act violations related to contracts with Iraqi Ministry of Health, remanded by Supreme Court (June 2024) with oral argument held (November 2024). Putative class action alleging ERISA fiduciary duty breaches related to prescription-drug benefits program, with second amended complaint filed (March 2025). Complaint against Ethicon Inc. alleging breach of contract and fraud related to Auris acquisition, with company appealing liability finding (September 2024). Antitrust lawsuit against Biosense Webster, Inc. by Innovative Health, LLC, with jury verdict in favor of Innovative Health (May 2025). Antitrust class action against Actelion Pharmaceutical Ltd. regarding TRACLEER, with trial scheduled for March 2026.

Stakeholder Impact

• Shareholders: Significant increase in net earnings due to talc reserve reversal, potential for continued regular quarterly cash dividends, but also increased debt and ongoing litigation risks.
• Employees: Restructuring programs in MedTech segments may impact employees through optimization of sites and exiting product lines. Employee compensation and stock option plans continue.
• Customers: Continued innovation and new product launches (e.g., CAPLYTA, Shockwave technology) aim to provide advanced healthcare solutions. Biosimilar competition for STELARA may lead to more affordable alternatives.
• Suppliers: Supplier finance programs with third-party financial institutions continue, with confirmed obligations of $0.7 billion as of June 29, 2025.
• Creditors: Increased long-term debt and commercial paper borrowings, but also access to substantial credit facilities and strong operating cash flows to fund obligations.

Next Steps

• Continue to monitor and assess the effectiveness of disclosure controls and procedures.
• Remeasure deferred tax balances related to NCTI for changes in tax rate and record an adjustment in the fiscal third quarter.
• Prepare for bellwether trials in consolidated proceedings in the California JCCP in November 2025 for talc claims.
• Prepare for bellwether trials in the New Jersey MCL in January 2026 for talc claims.
• Continue to defend remaining opioid cases brought by government entities and private litigants.
• Continue to monitor further developments regarding the EU's Pillar Two Directive and other global tax law changes.
• Continue to fund U.S. defined benefit plans to comply with the Pension Protection Act of 2006.
• Continue to fund international plans in accordance with local regulations.
• Complete the MedTech Surgery franchise restructuring program over the next two years.
• Substantially complete the Orthopaedics franchise restructuring program by the end of fiscal year 2025.
• Continue to monitor global capital markets and potentially raise capital when market conditions are favorable.

Key Dates

Recommendation

The significant reversal of the $7.0 billion talc litigation reserve is a major positive, substantially boosting net earnings and reducing a long-standing overhang. This, combined with strong operational growth in both Innovative Medicine and MedTech segments, driven by successful product launches and strategic acquisitions like Intra-Cellular Therapies and Shockwave Medical, indicates robust underlying business performance. While biosimilar competition for STELARA and increased debt are notable, the company's diversified portfolio, strong cash flow generation from operations, and proactive management of legal and tax matters position it favorably for future growth and profitability. The current valuation, considering the improved legal clarity and growth drivers, presents an attractive entry point for long-term investors.

Keywords

Pharmaceuticals, MedTech, Healthcare, Biotechnology, Oncology, Immunology, Neuroscience, Cardiovascular, Medical Devices, SEC Filing, Earnings Report, Acquisitions, Litigation, Talc, Opioids, Biosimilars, Patent Expiry, R&D, Financial Performance, Global Health